tiprankstipranks
Kamada Ltd (KMDA)
:KMDA
US Market
Holding KMDA?
Track your performance easily

Kamada (KMDA) Earnings Dates, Call Summary & Reports

338 Followers

Earnings Data

Report Date
Feb 12, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
0.05
Last Year’s EPS
0.1
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 12, 2018
|
% Change Since: 14.19%
|
Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue and EBITDA growth. The company showcased robust cash flow and strategic expansions in plasma collection and biosimilar products. However, there are ongoing challenges with FDA discussions and increased operating expenses. Overall, the highlights significantly outweigh the lowlights, indicating positive momentum.
Company Guidance
During Kamada's Q3 2024 earnings call, the company announced a robust financial performance with total revenues of $41.7 million, reflecting a 10% year-over-year increase. Adjusted EBITDA for the quarter reached $8.8 million, marking an 11% growth from the previous year. For the first nine months, revenues rose by 15% to $121.9 million, while adjusted EBITDA surged by 43% to $25.4 million, maintaining a 21% revenue margin. The company revised its full-year adjusted EBITDA guidance upward to between $32 million and $35 million, a 12% increase from prior guidance, and reaffirmed its revenue projection of $158 million to $162 million. Kamada reported strong cash flow with $37.2 million generated from operations, leading to a cash balance of $72 million. The call highlighted ongoing strategic initiatives, including expanding plasma collection centers and advancing the Phase III trial for the Inhaled AAT product, underscoring the company's continued commitment to double-digit growth.
Revenue and EBITDA Growth
Total revenues for Q3 were $41.7 million, a 10% increase compared to Q3 2023, and adjusted EBITDA was $8.8 million, an 11% increase. For the first 9 months, revenues were up 15% to $121.9 million, and adjusted EBITDA was $25.4 million, up 43% over the prior year.
Cash Flow and Financial Strength
Generated $37.2 million of cash from operations in the first 9 months, ending Q3 with $72 million in cash. This financial strength supports business development and M&A opportunities.
Expansion of Plasma Collection Centers
Opened a new plasma collection center in Houston with a capacity of over 50,000 liters annually, and construction of a third site in San Antonio is underway.
Biosimilar Product Launch
Launched the first biosimilar product in Israel, with several others in the pipeline, expected to reach peak potential annual sales of $30 million to $34 million.
Market Leadership in KEDRAB and CYTOGAM
Increased sales of KEDRAB and CYTOGAM, driving revenue growth, with KEDRAB holding a 40-50% market share.
---

Kamada (KMDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

KMDA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 07, 20182018 (Q2)
- / 0.14
0.137.69% (+0.01)
Nov 12, 20182018 (Q3)
- / -0.05
-0.001-5200.00% (-0.05)
Feb 12, 20192018 (Q4)
- / 0.45
0.156186.54% (+0.29)
May 14, 20192019 (Q1)
- / 0.13
0.034276.47% (+0.09)
Aug 06, 20192019 (Q2)
- / 0.16
0.1412.86% (+0.02)
Nov 13, 20192019 (Q3)
- / 0.15
-0.053379.25% (+0.20)
Feb 12, 20202019 (Q4)
- / 0.13
0.447-70.02% (-0.31)
May 18, 20202020 (Q1)
- / 0.13
0.128-1.56% (>-0.01)
Aug 12, 20202020 (Q2)
- / 0.09
0.158-44.30% (-0.07)
Nov 11, 20202020 (Q3)
- / 0.16
0.1485.41% (<+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

KMDA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2024$6.27$6.03-3.83%
Aug 14, 2024$5.55$5.33-3.96%
May 08, 2024$5.61$5.74+2.32%
Mar 06, 2024$6.37$6.05-5.02%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Kamada Ltd (KMDA) report earnings?
Kamada Ltd (KMDA) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
    What is Kamada Ltd (KMDA) earnings time?
    Kamada Ltd (KMDA) earnings time is at Feb 12, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is KMDA EPS forecast?
          KMDA EPS forecast for the fiscal quarter 2024 (Q4) is 0.05.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis